An announcement from Sana Biotechnology ( (SANA) ) is now available.
Sana Biotechnology, Inc. has undergone a leadership restructure with Steven D. Harr, M.D., the current President and CEO, stepping in as the acting Principal Financial Officer following Nathan Hardy’s resignation. Similarly, Susan Wyrick has been promoted from Senior Vice President to Acting Chief Financial Officer, Treasurer, and Principal Accounting Officer. Wyrick’s extensive experience in the biotech sector, including her previous roles at Juno Therapeutics and OncoGenex Pharmaceuticals, underscores her readiness for the interim role, which comes with additional compensation, including a monthly bonus and potential severance benefits. The company has ensured continuity and stability by promoting from within, signaling a seamless transition in financial leadership to its stakeholders.
See more insights into SANA stock on TipRanks’ Stock Analysis page.
